重新手术大动脉替换与内透导管大动脉替换用于退化生物假体的替换

Jake Awtry1, Thais Faggion Vinholo1, Mansoo Cho2

  • 1Division of Cardiac Surgery, Brigham and Women's Hospital, Boston, Massachusetts; Department of Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts.

PubMed
概括

重复手术大动脉置换 (redo-SAVR) 显示出比内透管大动脉置换 (ViV-TAVR) 更好的长期存活率,尽管最初的风险更高. 需要进一步的临床试验才能做出最佳的治疗决定.